Kenneth Adler, PhD
Allen F. Gant
Indu Parikh, PhD
TSC MEMBER INSTITUTION(S):
North Carolina State University
Environmental Protection Agency
National Institutes of Health
BIOMARCK PHARMACEUTICALS, LTD.
BREATHING NEW LIFE INTO RESPIRATORY TREATMENT
ABOUT THE COMPANY:
BioMarck Pharmaeceuticals, founded in 2002, is dedicated to the discovery and development of new drugs for the treatment of pulmonary diseases and disorders – such as bronchitis, asthma and cystic fibrosis — that are associated with the over-secretion of mucus and pulmonary inflammation. BioMarck’s Chief Scientist, Dr. Kenneth Adler of the Department of Molecular Biomedical Sciences at North Carolina State University (NCSU), is one of the best respected researchers in the field of airway disease. His research has been continuously funded by the National Institutes of Health for more than two decades and has also been supported by funding from the Environmental Protection Agency. His discoveries at NCSU provided the platform “MARCKS technology” for BioMarck.
BioMarck recently announced that the United States Patent and Trademark Office issued the company two new patents enhancing its intellectual property portfolio in support of its current lead drug for the treatment of chronic obstructive pulmonary disease.
UNIVERSITY-BASED RESEARCH CONNECTION:
BioMarck’s platform technology is based on the research of Dr. Kenneth Adler of the Department of Molecular Biomedical Sciences at North Carolina State University. BioMarck has licensed the “MARCKS technology” on a worldwide exclusive basis and includes therapeutic peptides and their analogs for the treatment of respiratory diseases related to mucus hypersecretion and inflammation in diseases such as asthma, COPD, cystic fibrosis, and rhinitis and certain non-respiratory diseases.
ROLE OF FEDERAL RESEARCH FUNDING:
Development of the MARCKS technology at NCSU was supported by funding from the National Institutes of Health and the Environmental Protection Agency.
Read The Full Report Here